- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.07. | Moss Genomics Inc: Moss Genomics contributes 200 ethereum to STRAT presale | 2 | Stockwatch | ||
| 11.07. | Moss Genomics Inc.: Moss Genomics Advances Blockchain Integration Strategy | 1.848 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is providing an update on its Ethereum (ETH) Treasury... ► Artikel lesen | |
| 19.06. | Moss Genomics Inc: Moss Genomics to acquire interest in Genomes.io | 1 | Stockwatch | ||
| MOSS GENOMICS Aktie jetzt für 0€ handeln | |||||
| 19.06. | Moss Genomics Inc.: Moss Genomics Announces Strategic Investment in Genomes.io | 326 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - June 19, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce that on June 18, 2025, it has... ► Artikel lesen | |
| 28.04. | Moss Genomics Inc: Moss launches Perennial, closes on 130 ethereum | 1 | Stockwatch | ||
| 28.04. | Moss Genomics Inc.: Moss Genomics Launches "Perennial" Genomics Platform, Closes on 130 ETH | 428 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce the public launch of its genomics... ► Artikel lesen | |
| 11.04. | Moss Genomics Inc: Moss Genomics lists on OTCQB Venture Market | 3 | Stockwatch | ||
| 11.04. | Moss Genomics Inc.: Moss Genomics Announces Listing on the OTC Markets | 395 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 11, 2025) - Moss Genomics Inc. (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) (the "Company" or "Moss") is pleased to announce that its common shares are... ► Artikel lesen | |
| 26.02. | Moss Genomics Inc: Moss Genomics appoints director, fractional CFO | 2 | Stockwatch | ||
| 26.02. | Moss Genomics Inc. Announces Leadership Changes | 186 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) ("Moss" or the "Company") is pleased to announce the appointment of Joseph De Pinto to... ► Artikel lesen | |
| 25.02. | Moss Genomics Inc: Moss Genomics doubles down on blockchain, ethereum | 1 | Stockwatch | ||
| 25.02. | Moss Genomics Inc.: Moss Genomics Announces Genomics Business Update, Integrating Blockchain for Genomic Security and Transparency | 188 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 25, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to provide an update on its business strategy... ► Artikel lesen | |
| 04.02. | Moss Genomics Inc.: Moss Genomics Announces Private Placement and Agreement to Acquire Ethereum | 568 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce a non-brokered private placement of up... ► Artikel lesen | |
| 01.02. | Moss Genomics Inc.: Moss Genomics Announces Closing of Private Placement, Acquisition of 160 Ethereum Cryptocurrency (ETH) and Welcomes Hunter Jordan to Its Board of Directors | 1.192 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 31, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce that is has closed its previously announced... ► Artikel lesen | |
| 24.01. | Moss Genomics Inc.: Moss Genomics Provides Corporate Update and Announces Shift in Business Strategy | 917 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to provide an update on the Company's operations and... ► Artikel lesen | |
| 14.01. | Moss Genomics Inc. Announces Successful German Listing on the Frankfurt Stock Exchange (FSE) | 306 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to announce that it has successfully listed... ► Artikel lesen | |
| 14.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 14.01.2025 | 377 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2025
Aktien
1 CA61965T1012 Moss Genomics Inc.
2... ► Artikel lesen | |
| 24.12.24 | Moss Genomics Inc.: Canadian Company Moss Genomics Announces Agreement to Acquire Ethereum, Appoints Jack Liu as CEO and Director, Private Placement and Option Grant | 802 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 24, 2024) - Moss Genomics Inc. (CSE: MOSS) (the "Company" or "Moss") today announced the appointment of Jack Liu as CEO and a Director of the... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | -0,24 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| EVOTEC | 6,356 | -2,37 % | Evotec-Aktie: Kurs heute im Minus (6,566 €) | Die Evotec-Aktie notiert heute etwas leichter. Das Papier kostete zuletzt 6,57 Euro. Heute hat sich an der deutschen Börse die Aktie von Evotec zwischenzeitlich um 3,13 Prozent verbilligt. Der Kurs... ► Artikel lesen | |
| DYNE THERAPEUTICS | 12,380 | -1,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | +1,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | +4,82 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| BIONTECH | 97,00 | -0,05 % | BioNTech: Hartnäckige Widerstände im Chart | Seit Monaten warten Anleger beim Mainzer Biotechnologieunternehmen auf den Befreiungsschlag. Immer wieder versuchen die Bullen, einen Aufwärtstrend zu starten, doch jeder Anstieg wurde bislang ebenso... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | -0,05 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| VALNEVA | 4,730 | -0,76 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,765 | +2,22 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| IMMUNOME | 10,280 | +3,32 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| LENZ THERAPEUTICS | 37,870 | -7,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | +0,91 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | +1,80 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | +3,33 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen |
Das Unternehmen MOSS GENOMICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,74 % bei einem Aktienkurs von 0,058 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOSS GENOMICS INC finden Sie auf Wallstreet Online.